---
title: "002550.SZ (002550.SZ) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/002550.SZ/news.md"
symbol: "002550.SZ"
name: "002550.SZ"
parent: "https://longbridge.com/zh-CN/quote/002550.SZ.md"
datetime: "2026-03-14T10:23:58.239Z"
locales:
  - [en](https://longbridge.com/en/quote/002550.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002550.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002550.SZ/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/002550.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002550.SZ/news.md)


# 002550.SZ (002550.SZ) — 相关新闻

### [Qianhong Bio-pharma: Discloses response to the inquiry letter regarding the issuance of convertible bonds to unspecified objects](https://longbridge.com/zh-CN/news/278531704.md)
*2026-03-10T10:05:23.000Z*
> Qianhong Bio-pharma announced that the company received an inquiry letter from the Shenzhen Stock Exchange regarding the

### [Qianhong Bio-pharma: Application for the issuance of convertible corporate bonds to unspecified objects has been accepted by the Shenzhen Stock Exchange](https://longbridge.com/zh-CN/news/273606118.md)
*2026-01-25T08:51:53.000Z*
> Qianhong Bio-pharma announced that on January 23, 2026, it received acceptance from the Shenzhen Stock Exchange for its 

### [Qianhong Bio-pharma disclosed a revised proposal for a CNY 1 billion convertible bond, increasing the investment in innovative drug research and development to CNY 410 million](https://longbridge.com/zh-CN/news/267194621.md)
*2025-11-24T13:22:53.000Z*
> On the evening of November 24th, Qianhong Bio-pharma (002550) announced the plan for issuing convertible corporate bonds

### [Qianhong Bio-pharma: Shareholder Zhao Gang terminates the reduction plan early](https://longbridge.com/zh-CN/news/266921016.md)
*2025-11-21T12:28:13.000Z*
> Qianhong Bio-pharma announced that shareholder Zhao Gang, who holds more than 5% of the shares, and his concerted partie

### [Qianhong Bio-pharma: The net profit for the third quarter was 125 million yuan, a year-on-year decrease of 1.28%](https://longbridge.com/zh-CN/news/263285826.md)
*2025-10-29T12:16:51.000Z*
> Qianhong Bio-pharma announced that its revenue for the third quarter was 353 million yuan, a year-on-year increase of 0.

### [Qianhong Bio-pharma: Warned for failing to disclose and halt trading in a timely manner when the shareholding ratio reached the 25% threshold](https://longbridge.com/zh-CN/news/257051400.md)
*2025-09-12T08:08:53.000Z*
> Qianhong Bio-pharma announced that shareholder Wang Ke increased his holdings in the company by 9.6 million shares throu

### [Qianhong Bio-pharma released its performance for the first half of the year, with a net profit attributable to the parent company of 258 million yuan, an increase of 41.17%](https://longbridge.com/zh-CN/news/254136558.md)
*2025-08-22T09:40:04.000Z*
> According to the Zhitong Finance APP, Qianhong Bio-pharma released its semi-annual report for 2025, showing an operating

### [Qianhong Bio-pharma shareholder Zhao Gang and his concerted actors plan to reduce their holdings by no more than 20.9 million shares](https://longbridge.com/zh-CN/news/251825607.md)
*2025-08-06T11:39:03.000Z*
> According to the Zhitong Finance APP, Qianhong Bio-pharma announced that the company's shareholder Mr. Zhao Gang and his

### [The concept of innovative drugs fluctuates and rebounds, ALK hits the limit and reaches a historical high](https://longbridge.com/zh-CN/news/249081285.md)
*2025-07-18T05:50:31.000Z*
> In the afternoon, the innovative drug concept fluctuated and rebounded, with the high-profile stock ALK hitting the dail

### [1,279 institutions conducted intensive research, the strongest leader in innovative drugs, dormant for 5 years, expected to explode 10 times](https://longbridge.com/zh-CN/news/248919481.md)
*2025-07-17T07:44:40.000Z*
> The main theme of the market in the second half of the year is innovative drugs, with 1,279 institutions conducting rese